Factors affecting the response of thalidomide therapy for patients with multiple myeloma
-
- AGATA Munehiko
- Department of Pharmacy, Tokyo Women's Medical University Hospital
-
- SAMESHIMA Yuichi
- Department of Hematology, Tokyo Women's Medical University
-
- ODA Tetsuro
- Department of Pharmacy, Tokyo Women's Medical University Hospital
-
- KONDO Toshiaki
- Department of Hematology, Tokyo Women's Medical University
-
- ISHIYAMA Midori
- Department of Hematology, Tokyo Women's Medical University
-
- YASUNAMI Takeshi
- Department of Hematology, Tokyo Women's Medical University
-
- KAZAMA Hiroshi
- Department of Hematology, Tokyo Women's Medical University
-
- OKAMURA Takamitsu
- Department of Hematology, Tokyo Women's Medical University
-
- YOSHINAGA Kentaro
- Department of Hematology, Tokyo Women's Medical University
-
- SHISEKI Masayuki
- Department of Hematology, Tokyo Women's Medical University
-
- MORI Naoki
- Department of Hematology, Tokyo Women's Medical University
-
- YAMADA Osamu
- Department of Hematology, Tokyo Women's Medical University
-
- SAGAWA Kenichi
- Department of Pharmacy, Tokyo Women's Medical University Hospital
-
- TERAMURA Masanao
- Department of Hematology, Tokyo Women's Medical University
-
- MOTOJI Toshiko
- Department of Hematology, Tokyo Women's Medical University
Bibliographic Information
- Other Title
-
- 多発性骨髄腫に対するthalidomide療法の効果に関与する因子と効果判定時期
- 臨床研究 多発性骨髄腫に対するthalidomide療法の効果に関与する因子と効果判定時期
- リンショウ ケンキュウ タハツセイ コツズイシュ ニ タイスル thalidomide リョウホウ ノ コウカ ニ カンヨ スル インシ ト コウカ ハンテイ ジキ
Search this article
Description
Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26). The complete response (CR) rate was 2.5%; partial response (PR) 50.0%; minimal response (MR) 25.0%; no change (NC) 12.5%; and progressive disease 10.0%. The response to thalidomide could be evaluated after four weeks of treatment. Significantly higher responses were associated with untreated patients, patients with combined use of thalidomide plus dexamethasone, and patients with kappa light chain. Patients who responded well to thalidomide showed a significantly higher progression-free survival (PFS) rate. In patients with kappa light chain, PFS and overall survival rates were significantly higher than those with lambda light chain. Frequent adverse reactions were numbness (47.5%), constipation (32.5%), and eruption (30.0%). In patients previously treated with vincristine, numbness occurred in a significantly higher percentage of patients.
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 51 (3), 189-195, 2010
The Japanese Society of Hematology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001205034869120
-
- NII Article ID
- 10026332405
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 10637231
-
- Text Lang
- ja
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- NDL Search
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed
